⌘ Services
mob-logo
Contact Us 800.227.0627
Contact Quote Order Login / Register

Lipid-Modified Oligonucleotides for Delivery & Cellular Uptake

Custom cholesterol, fatty acid, tocopherol, GalNAc-lipid, phospholipid and PEG-lipid oligonucleotide conjugates designed to improve cellular uptake, membrane interaction, tissue distribution, pharmacokinetics and formulation performance for DNA, RNA, antisense, siRNA and therapeutic research workflows.

Cholesterol • Fatty Acids • Tocopherol DSPE • DSPE-PEG • Ionizable Lipids GalNAc-Lipid • Lipid-siRNA • Lipid-ASO HPLC/SEC • ESI-MS/MALDI • Endotoxin
Discuss a Lipid-Oligo Design Explore Lipid Conjugates
Overview Delivery Platforms Objective Selector Lipid Library Incorporation Applications Troubleshooting FAQ Contact
Scientific Overview

Lipid-Modified Oligonucleotides for Delivery, Uptake and Formulation Research

Bio-Synthesis provides custom lipid-modified DNA and RNA oligonucleotides, including ASOs, siRNA, aptamers, probes and other nucleic-acid constructs. Sterols, saturated and unsaturated fatty acids, phosphatidylethanolamine lipids, PEG-lipids and vitamin-derived lipids can be used to influence membrane association, cellular uptake, serum-protein interaction, biodistribution, circulation and formulation behavior.

Performance depends on the complete molecular architecture—not simply the lipid name. Lipid class, terminal or internal placement, linkage, spacer, oligonucleotide modality, incorporation route, purification strategy and formulation conditions should be planned together. Lipids may also be combined with GalNAc, peptides, fluorophores, biotin or bioorthogonal handles when multifunctional delivery or analytical readouts are required.

Design principle: begin with the biological or formulation objective, then select the lipid architecture, placement and incorporation route that preserve oligonucleotide function while providing the required delivery behavior.

Lipid & Delivery Conjugation Platforms

Representative Conjugation Strategies for Delivery, Targeting and Formulation

Lipid delivery conjugation platforms
⌕ Click to Enlarge
Representative lipid and delivery conjugation platforms
Mem

Direct Membrane Association

Cholesterol, tocopherol and fatty-acid anchors increase hydrophobic association with cell membranes, model bilayers and membrane-derived systems.

Alb

Serum-Protein Interaction

Selected long-chain lipids can interact with albumin or other circulating proteins, influencing exposure, distribution and pharmacokinetic behavior.

LNP

Particle & Liposome Anchoring

DSPE, DOPE, DPPE and PEG-lipids support presentation on liposomes, micelles, lipid nanoparticles and other formulated delivery systems.

Multi

Targeted & Multifunctional Delivery

Lipid anchors can be integrated with GalNAc, peptides, reporters or affinity handles when receptor targeting, tracking or surface display is required.

Interactive Research Objective Selector

Choose a Lipid Strategy by Research Objective

Select the closest project goal to compare recommended lipid strategies, compatible oligonucleotide formats, incorporation routes, and practical design considerations. These are starting recommendations; final selection depends on sequence, placement, formulation, target system, and analytical requirements.

Recommended Starting Strategy

Improve Cellular Uptake

Use a lipophilic anchor that increases membrane and serum interaction while preserving oligonucleotide solubility, duplex behavior, and productive intracellular delivery.

Recommended Lipids
Best-Fit Oligo Formats
Typical Architecture & Route
Key Design Considerations
    TIP
    Bio-Synthesis Design Guidance

    Lipid Modification Library

    Lipid Chemistry & Incorporation Guide

    Select a lipid family to compare representative modifiers, intended function, preferred incorporation route, and typical oligonucleotide applications. The recommended route depends on reagent availability, lipid stability, conjugation position, spacer design, and purification requirements.

    How should I interpret "phosphoramidite available"?
    Terminal Modifier Amidite
    Terminal lipid incorporation

    A dedicated lipid modifier amidite introduces the lipid at the 5′ terminus during automated synthesis. A related functionalized CPG may be used for a defined 3′ lipid.

    Examples: palmitamido-C6, stearamido-C7, cholesteryl-TEG and tocopherol-TEG.

    Modified Nucleoside Amidite
    Internal site-specific lipid incorporation

    A lipid chain is built into a modified nucleoside monomer and placed at a selected nucleotide position during synthesis.

    Examples: 2′-O-C16 and 2′-O-C22 nucleoside phosphoramidites.

    These architectures create different linkages and placements. A terminal C16 conjugate and an internal 2′-O-C16 modification should therefore be treated as separate designs when selecting reagents, quoting, purifying, and documenting the final oligonucleotide.

    Representative single, dual, and triple saturated fatty acid siRNA conjugates using myristic and docosanoic acid architectures
    ⌕ Click to Enlarge
    Representative Single-, Dual-, and Multi-Lipid Architectures. Illustrative myristic-acid and docosanoic-acid siRNA conjugates showing increasing lipid valency.
    Primary use

    uptake, albumin interaction, and membrane anchoring

    Route

    amidite, CPG, or post-synthetic conjugation

    Design focus

    chain length, lipid valency, spacer, and placement

    Watch

    aqueous solubility, aggregation, and purification complexity

    Design principle: increasing lipid valency may strengthen membrane or protein interactions, but it can also reduce aqueous solubility and increase chromatographic complexity. Single-, dual-, and triple-lipid designs should be evaluated as distinct architectures.
    Lipid / Architecture Code Placement Available Route Preferred Method Typical Application
    Lauric Acid (C12) Terminal Conjugate [C12] Usually 5′ or 3′ Post-Synthetic Custom Amidite Possible Amide coupling unless a validated project-specific reagent is available Albumin interaction, circulation, and lipid SAR studies
    Myristic Acid (C14) Terminal Conjugate [C14] Usually 5′ or 3′ Post-Synthetic Custom Amidite Possible Activated fatty-acid coupling for most projects ASO and siRNA uptake screening
    Palmitamido-C6 / Palmitate (C16) [C16] 5′ by amidite; 3′ by CPG; terminal post-conjugation also possible Phosphoramidite CPG Post Direct terminal incorporation when the validated reagent fits the design C16-ASO, C16-siRNA, and extrahepatic delivery studies
    2′-O-C16 Nucleoside Modification [2′-O-C16] Internal or selected terminal nucleotide position Nucleoside Phosphoramidite Direct automated synthesis using the appropriate 2′-O-C16 A, C, G, or U monomer Site-specific lipophilic modification in siRNA and therapeutic RNA designs
    Stearamido-C7 / Stearate (C18) [C18] 5′ by amidite; 3′ by CPG where available; post-conjugation also possible Phosphoramidite CPG Post Direct terminal incorporation when a validated stearamido reagent is appropriate Albumin binding, uptake, and pharmacokinetic tuning
    Arachidic Acid (C20) Terminal Conjugate [C20] Usually terminal Post-Synthetic Custom Amidite Possible Post-synthetic coupling unless a validated custom reagent is supplied High-lipophilicity and membrane-retention studies
    Behenic / Docosanoic Acid (C22) Terminal Conjugate [C22] Usually terminal Post-Synthetic Custom Amidite Possible Post-synthetic coupling for a true terminal fatty-acid conjugate Advanced lipid SAR and strong hydrophobic anchoring
    2′-O-C22 Nucleoside Modification [2′-O-C22] Internal or selected nucleotide position Nucleoside Phosphoramidite Direct automated synthesis using 2′-O-C22-modified nucleoside monomers Site-specific extrahepatic delivery designs in siRNA and dsRNA
    Representative single, dual, and triple unsaturated fatty acid siRNA conjugates using DHA and EPA architectures
    ⌕ Click to Enlarge
    Representative Mono-, Di-, and Multi-Lipid Unsaturated Fatty Acid Architectures. Illustrative DHA and EPA siRNA conjugates showing increasing lipid valency.
    Primary use

    membrane interaction, fluidity, uptake, and distribution studies

    Route

    usually post-synthetic conjugation

    Design focus

    unsaturation level, lipid valency, spacer, and placement

    Watch

    oxidation, storage stability, solubility, and purification

    Design principle: unsaturated lipids can alter membrane interaction and biodistribution, while higher unsaturation may increase oxidative sensitivity. DHA and EPA conjugates require route, handling, and storage conditions matched to the final architecture.
    Lipid Code Function Available Route Preferred Method Typical Application
    Oleic Acid (C18:1) [C18:1] Monounsaturated lipid supporting membrane interaction and fluidity Post-Synthetic Amide coupling to amino oligo Membrane insertion and uptake studies
    Linoleic Acid (C18:2) [C18:2] Polyunsaturated lipid for delivery and hydrophobicity screening Post-Synthetic Activated lipid coupling under controlled conditions Lipid SAR and uptake optimization
    α-Linolenic Acid (C18:3) [ALA] Omega-3 lipid for exploratory delivery and tissue-distribution studies Post-Synthetic Amide or click-mediated conjugation Exploratory lipid-delivery research
    Arachidonic Acid (C20:4) [ARA] Highly unsaturated lipid for membrane and signaling-related studies Post-Synthetic Case-specific coupling with oxidation control Membrane biology and delivery screening
    Eicosapentaenoic Acid [EPA] Omega-3 lipid for uptake and biodistribution research Post-Synthetic Activated ester or click conjugation siRNA and lipid SAR studies
    Docosahexaenoic Acid [DHA] Polyunsaturated lipid associated with membrane interaction and tissue distribution Post-Synthetic Post-synthetic conjugation with stability controls DHA-siRNA and delivery research
    Representative phosphatidylethanolamine oligo conjugate structures including PE, DHPE, soy PE, DOPE, and DSPE
    ⌕ Click to Enlarge
    Representative PE Conjugate Structures
    Primary use

    liposomes, membranes and LNP display

    Route

    post-synthetic conjugation

    Design focus

    PEG length and reactive terminus

    Watch

    solubility and formulation behavior

    Lipid Code Function Available Route Preferred Method Typical Application
    DOPE [DOPE] Unsaturated PE lipid supporting membrane fusion and liposome systems Post-Synthetic Reactive DOPE derivative coupled to oligo handle Liposomes, membrane probes and formulation research
    DPPE [DPPE] Saturated PE lipid for stable bilayer insertion Post-Synthetic Amide, maleimide or click coupling Membrane display and particle functionalization
    DSPE [DSPE] Long-chain PE anchor commonly used in liposomes and LNPs Post-Synthetic DSPE-PEG reactive derivative preferred LNP, liposome and micelle systems
    DSPE-PEG2000 [DSPE-PEG2000] Combines membrane anchoring with PEG spacing and surface display Post-Synthetic Maleimide, NHS or click-functional DSPE-PEG LNP-facing oligos and nanoparticle display
    DSPE-PEG-Maleimide [DSPE-PEG-Mal] Thiol-reactive PEG-lipid for selective oligo attachment Post-Synthetic 5′-thiol oligo + maleimide lipid Surface display and nanoparticle conjugation
    DSPE-PEG-NH2 [DSPE-PEG-NH2] Amine-functional PEG-lipid for activated coupling strategies Post-Synthetic Activated carboxyl or heterobifunctional linker Custom lipid-oligo architectures
    Representative cholesterol and sterol oligonucleotide conjugates including cholesterol derivatives, phytosterols, biosynthetic sterols, DHEA, diosgenin, and pregnenolone
    ⌕ Click to Enlarge
    Representative Sterol–Oligonucleotide Conjugates. Illustrative cholesterol derivatives, phytosterols, sterol biosynthetic intermediates, and related steroidal architectures available for custom feasibility review.
    Primary use

    uptake and membrane association

    Route

    amidite, CPG or post-synthetic

    Design focus

    sterol identity, terminal placement and spacer

    Watch

    hydrophobic purification and sterol-specific feasibility

    Lipid Code Function Available Route Preferred Method Typical Application
    Cholesterol [Chol] Widely used sterol for cellular uptake and membrane interaction Amidite CPG Post Direct synthesis when placement and reagent allow Cholesterol-siRNA, ASO and probe delivery
    Cholesteryl-TEG [Chol-TEG] Cholesterol with hydrophilic spacer to reduce steric interference Amidite Post Direct phosphoramidite incorporation Duplex-compatible lipid attachment
    3′-Cholesterol CPG [3′-Chol] Introduces cholesterol at the 3′ terminus from the solid support Solid Support Cholesterol-functionalized CPG 3′-lipidated oligos and siRNA passenger strands
    Hydroxyprolinol Cholesterol [Hyp-Chol] Rigid sterol attachment architecture for advanced delivery studies Amidite Custom Case-specific direct incorporation Therapeutic research and sterol SAR
    Cholesterol-PEG [Chol-PEG] Combines membrane affinity with PEG spacing and shielding Post-Synthetic Reactive PEG-linked cholesterol conjugation Micelles, particles and circulation tuning
    Representative steroid oligonucleotide conjugates including cortisol, DHEA, 17-alpha-hydroxyprogesterone, aldosterone, estradiol, and testosterone
    ⌕ Click to Enlarge
    Representative Steroid–Oligonucleotide Conjugates. Illustrative corticosteroid, androgen, estrogen, and steroid-hormone scaffolds for custom conjugation and feasibility review.
    Primary use

    receptor biology, uptake, and tissue-distribution studies

    Route

    usually post-synthetic; selected amidites may be feasible

    Design focus

    accessible hydroxyl, carbonyl, or linker handle and spacer placement

    Watch

    steroid-specific reactivity, solubility, and biological activity

    Lipid Code Function Available Route Preferred Method Typical Application
    α-Tocopherol / Vitamin E [Toc], [VitE] Lipophilic antioxidant used in uptake and biodistribution research Amidite Post Direct amidite or TEG-spaced reagent Tocopherol-siRNA and ASO delivery
    Tocopherol-TEG [Toc-TEG] Spacer-equipped tocopherol for improved accessibility Amidite Direct phosphoramidite incorporation Duplex-compatible tocopherol conjugates
    Vitamin D3 [VitD3] Highly hydrophobic steroid-derived vitamin for specialized delivery studies Post-Synthetic Activated linker or click conjugation Tissue-distribution and sterol-like SAR studies
    Custom Steroid Derivative [Steroid] Custom steroid scaffold selected for uptake, receptor, or membrane studies Case-by-Case Feasibility review and linker design Custom delivery and receptor-directed research

    Route selection is project-specific. A lipid listed as directly incorporable may still be better introduced post-synthetically when the sequence is long, the construct is multifunctional, the lipid is needed internally, or purification and scale favor a separate conjugation step.

    Incorporation Strategy

    How Lipids Are Incorporated into Oligonucleotides

    Lipids can be introduced by phosphoramidite synthesis, a functionalized 3′ solid support, or post-synthetic coupling. Route selection must define the exact lipid architecture, linkage, placement, spacer, stability, scale, and purification strategy.

    1

    Direct Phosphoramidite Incorporation

    Used when a compatible lipid phosphoramidite is available and stable under oligonucleotide synthesis and deprotection conditions.

    Lipid Amidite → Automated Synthesis → Deprotection → Purification

    Typical examples: Cholesteryl-TEG, selected C16/C18 reagents, tocopherol-TEG, and other commercially available lipid amidites.

    2

    Functionalized Solid Support

    Used primarily for defined 3′ lipid placement. The oligonucleotide is assembled from a lipid-bearing CPG support.

    Lipid-CPG → Oligo Chain Growth → Cleavage → 3′ Lipid Oligo

    Typical examples: 3′-cholesterol CPG and other validated lipid-functionalized supports.

    3

    Post-Synthetic Conjugation

    Preferred for large phospholipids, PEG-lipids, oxidation-sensitive unsaturated lipids, customer-supplied lipids, and multifunctional constructs.

    Reactive Oligo + Activated Lipid → Conjugation → RP-HPLC / SEC

    Typical examples: DSPE, DOPE, DPPE, DSPE-PEG, DHA, EPA, vitamin D3, lipid-dye, and lipid-peptide architectures.

    Post-Synthetic Handle Selection

    Choose a Complementary Oligo–Lipid Coupling Pair

    Each card shows the essential chemistry only. Final conditions depend on oligo sequence, lipid solubility, placement, scale, and purification behavior.

    5′ / 3′ Amine

    Amide
    Lipid partner

    NHS ester or activated carboxyl

    Best fit

    Fatty acids, PEG-lipids, steroids

    Design tip

    Add C6, TEG, or PEG when separation is needed.

    5′ / 3′ Thiol

    Maleimide
    Lipid partner

    Maleimide-functional lipid

    Best fit

    DSPE-PEG and surface display

    Design tip

    Control thiol oxidation and maleimide hydrolysis.

    Azide

    SPAAC
    Lipid partner

    DBCO- or BCN-functional lipid

    Best fit

    Large or multifunctional lipids

    Design tip

    Copper-free coupling suits sensitive RNA constructs.

    Alkyne

    CuAAC
    Lipid partner

    Azide-functional lipid

    Best fit

    Custom robust conjugates

    Design tip

    Plan copper removal and compatibility testing.

    Aminooxy

    Oxime
    Lipid partner

    Aldehyde or ketone lipid

    Best fit

    Orthogonal carbonyl coupling

    Design tip

    Useful when amine or thiol chemistry must remain free.

    Hydrazide

    Hydrazone
    Lipid partner

    Aldehyde-functional lipid

    Best fit

    Specialty carbonyl lipids

    Design tip

    Match linkage stability to the intended assay.

    Spacer Selection

    C6, TEG, PEG, or custom spacers can reduce steric hindrance and preserve hybridization.

    Conjugation Position

    5′ and 3′ placement are generally easiest to manufacture and characterize; internal placement requires case-specific design.

    Purification

    Hydrophobic conjugates usually require RP-HPLC; large or self-associating constructs may also benefit from SEC.

    Custom Lipids

    Customer-supplied lipids can be evaluated for functional group, solubility, stability, linker needs, and analytical feasibility.

    Saturated Fatty Acids

    Selected Amidites Selected CPG Post-Synthetic

    Define terminal fatty-acid conjugation versus internal 2′-O-C16/C22 placement before route selection.

    Route note

    Validated terminal C16/C18 reagents and modified nucleoside monomers support direct incorporation; other chains may favor conjugation.

    Unsaturated Fatty Acids

    Post-Synthetic Preferred Case-Specific Direct

    Post-synthetic coupling is generally preferred because unsaturated lipids can be oxidation-sensitive.

    Route note

    Use controlled handling, appropriate spacer design, and stability-aware purification.

    Phosphatidylethanolamine Lipids

    Post-Synthetic

    DOPE, DPPE, DSPE, and DSPE-PEG are usually coupled through reactive PEG-lipid derivatives.

    Route note

    Thiol–maleimide, amide, or click coupling is selected according to the lipid reagent and oligo handle.

    Cholesterol & Sterols

    Amidite CPG Post-Synthetic

    Direct amidite or cholesterol CPG is typically preferred for routine terminal placement.

    Route note

    Alternative sterols may require custom linker design and feasibility review.

    Tocopherol & Steroid-Derived Lipids

    Selected Amidites Post-Synthetic

    Use validated direct reagents when available; otherwise select a functional handle for conjugation.

    Route note

    Steroid-specific functional groups, biological activity, and linker accessibility require case-by-case review.

    Custom or Multifunctional Lipids

    Feasibility Review Post-Synthetic Common

    Route selection depends on functional group, stability, solubility, placement, and scale.

    Route note

    Provide the exact lipid structure, reactive group, target placement, quantity, and intended application.

    Route labels: Direct = phosphoramidite incorporation CPG = functionalized 3′ solid support Post-synthetic = coupling to a preinstalled oligo handle

    Important: “Post-synthetic” applies to the specified conjugate architecture; it does not mean that every lipid with the same carbon-chain length lacks a phosphoramidite route. The oligonucleotide must first be manufactured with the correct reactive handle, spacer, and placement. The lipid reagent must carry a complementary functional group, and the final conjugate requires dedicated purification and identity confirmation.

    Application-Centered Design

    Match Lipid Chemistry to the Oligo Modality

    The best lipid depends on oligo type, target tissue, formulation plan, readout and whether delivery is direct or carrier-assisted.

    Recommended lipids

    Cholesterol, C16/C18 fatty acids, GalNAc-lipid, tocopherol and PEG-lipid options.

    Design Focus

    Place lipids at termini when possible; add PEG spacers to preserve hybridization and reduce steric effects.

    Readout

    Cell uptake, target knockdown, serum stability, PK/PD and tissue exposure.

    Recommended lipids

    Cholesterol-siRNA, DHA-siRNA, tocopherol-siRNA, GalNAc-lipid siRNA and lipid-DsiRNA constructs.

    Design Focus

    Confirm guide/passenger placement, duplex activity and any spacer needed between lipid and RNA duplex.

    Readout

    Cellular uptake, RISC activity, target mRNA/protein knockdown and biodistribution.

    Recommended lipids

    DSPE, DSPE-PEG, DAG, TAG, ionizable lipids and custom LNP-compatible anchors.

    Design Focus

    Align lipid anchor, PEG length and oligo placement with particle formulation and release goals.

    Readout

    Particle incorporation, size/PDI, release, potency and formulation stability.

    Recommended lipids

    Lipid-fluorophore oligos, lipid-biotin oligos, phospholipid probes and membrane-anchor oligos.

    Design Focus

    Balance hydrophobic anchoring with fluorescent signal, background, and surface or membrane compatibility.

    Readout

    Microscopy, flow cytometry, pull-down, surface display or membrane model assay.
    Targeting & Multifunctional Conjugates

    Targeting & Multifunctional Lipid-Oligo Architectures

    Targeting ligands, reporters, affinity tags, peptides, and formulation lipids are better treated as multifunctional architectures rather than basic lipid classes.

    GalNAc–Lipid Conjugates

    Combine hepatocyte targeting with membrane-affinity or formulation-oriented lipid functionality.

    Lipid–Peptide–Oligo Conjugates

    Integrate lipid delivery with peptide targeting, uptake, trafficking, or receptor-binding motifs.

    Lipid–Fluorophore Oligos

    Combine membrane association or uptake enhancement with imaging and biodistribution readouts.

    Lipid–Biotin Oligos

    Pair a hydrophobic anchor with affinity capture for pull-down, bead, membrane, or surface studies.

    Ionizable & LNP-Compatible Lipids

    Support pH-responsive, particle-facing, or formulation-dependent oligonucleotide delivery systems.

    Customer-Supplied Lipids

    Evaluate custom lipid reagents, linker requirements, orthogonal chemistry, purification, and analytical feasibility.

    Interactive Troubleshooting Guide

    Diagnose Common Lipid-Oligonucleotide Design and Manufacturing Problems

    Select the issue closest to what you are observing to review likely causes, practical design responses, and recommended verification steps.

    Poor aqueous solubility or aggregation

    Hydrophobic lipid conjugates may self-associate during purification, concentration, storage, or reconstitution.

    Observed result

    What you may see

      →
      Likely causes

      What to investigate

        →
        Design response

        Practical next steps

          Recommended verification:

          Integrated Development Workflow

          From Lipid-Oligo Design to Characterized Product Delivery

          Lipid selection, incorporation route, purification, analytical confirmation, formulation, and delivery requirements are planned as one connected development process.

          1
          Design

          Lipid class, oligo modality, placement, spacer, reactive handle, application, and formulation objectives

          2
          Manufacture

          Direct phosphoramidite synthesis, lipid-functionalized CPG, or post-synthetic conjugation with scale-aware process planning

          3
          Characterize

          RP-HPLC purity, ESI-MS or MALDI identity, optional SEC, yield, lipid placement, and project-specific release testing

          4
          Deliver

          Lyophilized or formulated product, storage and reconstitution guidance, documentation, traceability, and scale-up support

          Project-specific testing: Endotoxin, residual solvents, moisture, stability, salt or counterion analysis, particle compatibility, or custom documentation can be added when required by the intended research or development workflow.
          Before Requesting a Quote

          Information Helpful for Lipid-Oligo Projects

          Oligo Type
          DNA, RNA, ASO, siRNA
          Lipid
          Chol, C16, DSPE, GalNAc
          Placement
          5′, 3′, internal, duplex
          Spacer
          TEG, PEG, custom
          Scale
          nmol to gram
          QC
          HPLC, MS, SEC, endotoxin
          Contact & Quote Request

          Need help choosing a lipid conjugate?

          Share your sequence, modality, lipid type, placement, spacer preference, formulation plan, scale, purification grade, QC requirements, storage needs and delivery format. Bio-Synthesis can help recommend a practical lipid-oligo design path.
          Request a Quote Speak to a Scientist

          Need help before quoting?

          Email: info@biosyn.com
          Phone: 800-227-0627 (US/CAN)
          Phone: +001-972-420-8505 (INT)

          Design Review

          Compare cholesterol, fatty acids, tocopherol, DSPE-PEG, GalNAc–lipid architectures and custom lipid architectures.

          Chol C16 DSPE GalNAc

          QC & Handling Package

          Plan HPLC, MS, optional SEC, endotoxin, stability, storage and reconstitution instructions.

          HPLC MS SEC Storage
          Quality Systems & Manufacturing Support

          Controlled Support from Lipid-Oligo Design Through Release

          QMS

          ISO-Supported Lipid-Oligonucleotide Manufacturing

          Lipid-modified oligonucleotides are supported by documented synthesis, conjugation, purification, analytical characterization, traceability, project-specific handling, and scalable development pathways.

          Certified Quality Systems ISO 9001:2015, ISO 13485:2016, and ISO 14001-supported operations.
          Documented Lipid Chemistry Defined lipid structure, linkage, placement, spacer, reagent format, and incorporation route.
          Analytical Characterization RP-HPLC purity, ESI-MS or MALDI identity, optional SEC, and project-specific release testing.
          Flexible Development Support Feasibility, pilot production, repeat manufacturing, formulation guidance, documentation, and larger-scale pathways.

          Lipid-Modified Oligonucleotide FAQ

          FAQ

          How should lipid-modified oligonucleotides be stored?
          For long-term storage, lipid-modified oligonucleotides are typically stored dry at −20°C in a light-protected environment. Avoid repeated freeze-thaw cycles. Storage recommendations may vary by lipid chemistry, conjugate architecture and formulation.
          How should lipid-modified oligonucleotides be reconstituted?
          Most lipid-conjugated oligonucleotides can be reconstituted in nuclease-free water, TE buffer, PBS or formulation-specific buffers. Highly hydrophobic conjugates may require gentle warming, extended mixing, sonication, a small amount of compatible organic co-solvent or specialized formulation conditions.
          Are lipid-modified oligos harder to dissolve than standard oligos?
          Yes. Hydrophobic lipids such as cholesterol, tocopherol and long-chain fatty acids can reduce aqueous solubility or promote self-association. Start with the recommended concentration and buffer, then adjust mixing, temperature or formulation as needed.
          What QC is recommended for lipid-oligo conjugates?
          HPLC or RP-HPLC purity and ESI-MS/MALDI identity are recommended. SEC, endotoxin, residual solvent, moisture, stability and custom release documentation can be added depending on the application.
          Will lipid conjugation change duplex stability or activity?
          It can. Lipids may introduce steric effects, hydrophobic aggregation or altered duplex behavior. PEG or TEG spacers are often used to preserve hybridization and reduce self-association.
          How do I choose 5′, 3′ or internal lipid placement?
          Terminal lipid placement is usually the easiest to synthesize, purify and interpret. Internal placement is possible but should be designed with spacers and piloted to confirm Tm, hybridization, duplex activity and functional potency.
          Which lipids are best for siRNA versus ASO?
          For siRNA, cholesterol, DHA, tocopherol, GalNAc-lipids and DSPE-PEG are common starting points depending on route and formulation. For ASO, cholesterol, C16/C18 fatty acids, tocopherol and GalNAc-lipid options are commonly evaluated for uptake and PK tuning.
          Can lipids be combined with GalNAc, dyes, peptides or biotin?
          Yes. Multifunctional lipid oligos can combine lipids with GalNAc, fluorescent dyes, peptides, biotin, PEG or bioorthogonal handles when spacing, chemistry and purification are planned carefully.
          More FAQsAll FAQs
          Recommended Reading

          Recommended Reading & Literature References

          1. Wolfrum C, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotechnology. 2007;25:1149–1157.
          2. Nair JK, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. Journal of the American Chemical Society. 2014;136(49):16958–16961.
          3. Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Research. 2016;44(14):6518–6548.
          4. Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Therapeutics. 2018;28(3):109–118.
          5. Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nature Biotechnology. 2017;35:238–248.
          6. Juliano RL, Ming X, Carver K, Laing B. Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology. Nucleic Acid Therapeutics. 2014;24(2):101–113.
          7. Biscans A, et al. The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo. Journal of Controlled Release. 2019;302:116–125.

          Scientific note: References provide background on lipid conjugation, delivery, valency, and oligonucleotide trafficking. Final design should be evaluated in the context of sequence, modality, lipid chemistry, placement, spacer, formulation, solubility, purification, and analytical requirements.

          Why Choose Bio-Synthesis

          Trusted by biotech leaders worldwide for over 45 years of delivering high-quality, fast, and scalable synthetic biology solutions.

          Greetings, Researchers,

          Please be advised that any information, guidelines, write-ups, and oral/video/graphic content on our website are intended solely as general guidelines.

          It is the researcher's sole responsibility to conduct thorough research on the design of products intended for their experiments before submitting
          their designs to Biosynthesis for production feasibility review.

          Thank you for your understanding.

          Quick Links